Metformin displayed a lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had the highest risk.
New report calls for more research on women’s health issues
Jul 12, 2024
The National Academies of Sciences, Engineering and Medicine analysis noted that women are disproportionately affected by chronic illnesses, including Alzheimer’s disease, depression and osteoporosis.
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Cognitive impairment delayed with genetic variant
Jun 20, 2024
The onset of cognitive impairment was delayed among those heterozygous for the apolipoprotein E3 Christchurch variant.
Lifestyle intervention can improve cognition, function in early Alzheimer’s disease
Jun 13, 2024
A significant correlation was seen between lifestyle and both cognitive function and Aβ42/40 ratio.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
Study identifies factors that predict driving cessation in seniors
May 22, 2024
Older age, female sex and progression to symptomatic Alzheimer’s disease were associated with driving cessation.
Benefit of thick liquids in Alzheimer’s disease and dysphagia unclear
May 06, 2024
Patients receiving thick versus thin liquids were less likely to be intubated and more likely to have respiratory complications.
Distance to neurologist, PCP may explain Alzheimer’s disease disparities
Apr 05, 2024
Non-Hispanic American Indian and/or Alaska Native and Hispanic decedents have to travel further to neurologist than non-Hispanic whites.
Higher education may protect functioning with Alzheimer’s disease
Apr 03, 2024
The findings were seen among African American individuals, with greater protective effect in APOE ɛ4 noncarriers.